When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. A new year is a great time for resolutions, and if you're looking to spend 2025 spending ...
The Repair Shop viewers were moved as the show featured boots owned by a blind photographer who said his footwear made him feel he could "conquer the world”. The latest episode of the BBC series ...
The Repair Shop viewers were moved as the show featured boots owned by a blind photographer who said his footwear made him feel he could "conquer the world”. The latest episode of the BBC series — ...
His momentum carried him near the baseline out of bounds, but he had enough awareness to fire a blind over-the-head pass. Teammate Aaron Gordon was sprinting down the floor himself, and caught the ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. There is an argument that, when buying a new phone, the color isn't all that important as ...
If it weren’t for hunting blinds, I might not have killed my first deer as a kid. I was barely a teen, and had just started hunting on my own. I was anything but stealthy. My dad made the wise ...
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders
(AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central ...
(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...
Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session.
Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will ...
J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...
Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback